Ceftonus powder for solution for injection

국가: 아르메니아

언어: 영어

출처: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

유효 성분:

ceftriaxone (ceftriaxone sodium)

제공처:

Panpharma

ATC 코드:

J01DD04

INN (International Name):

ceftriaxone (ceftriaxone sodium)

복용량:

1000mg

약제 형태:

powder for solution for injection

패키지 단위:

(25) glass vial

처방전 유형:

Prescription

승인 상태:

Registered

승인 날짜:

2022-10-12

제품 특성 요약

Company: PANPHARMA
Product:
Ceftonus 1 g, Powder for solution for injection
Module1
1
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
CEFTONUS, 1 G, POWDER FOR SOLUTION FOR INJECTION
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Ceftriaxone
As ceftriaxone sodium
....................................................................................................................................
1 g
For one vial flacon.
Excipient with a known effect: sodium (83 mg per vial).
For the complete list of excipients, please see section 6.1.
3. PHARMACEUTICAL FORM
Powder for solution for injection or for infusion.
4.CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Ceftriaxone is indicated for the treatment of the following infections
in adults and children including term
neonates (from birth):
Bacterial Meningitis
Community acquired pneumonia
Hospital acquired pneumonia
Acute otitis media
Intra-abdominal infections
Complicated urinary tract infections (including pyelonephritis)
Infections of bones and joints
Complicated skin and soft tissue infections
Gonorrhoea
Syphilis
Bacterial endocarditis.
Ceftriaxone may be used:

For treatment of acute exacerbations of chronic obstructive pulmonary
disease in adults.

For treatment of disseminated Lyme borreliosis (early (stage II) and
late (stage III)) in adults and
children including neonates from 15 days of age.

For Pre-operative prophylaxis of surgical site infections

In the management of neutropenic patients with fever that is suspected
to be due to a bacterial
infection.

In the treatment of patients with bacteraemia that occurs in
association with, or is suspected to be
associated with, any of the infections listed above.
Ceftriaxone should be co-administered with other antibacterial agents
whenever the possible range of causative
bacteria would not fall within its spectrum (see section 4.4).
Company: PANPHARMA
Product:
Ceftonus 1 g, Powder for solution for injection
Module1
2
Consideration should be given to official guidelines on the
appro